PURA - Puration Anticipate EVERx CBD Sports Water Sales Boost From Cannabis 2.0
15 Octobre 2019 - 4:38PM
InvestorsHub NewsWire
PURA – Puration Anticipate EVERx
CBD Sports Water Sales Boost From Cannabis 2.0
Dallas, TX -- October 15, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced an anticipated sales boost from Cannabis
2.0 – the legalization of cannabis infused edibles and beverages in
Canada going into effect later this week on October
17th. PURA management has observed a movement in
Canada toward CBD infused sports nutrition beverages. Both
Aurora Cannabis (ACB)
and Canopy Growth (CGC)
have made recent moves into the sports nutrition beverage
sector. Aurora has entered into a deal with the UFC and
Canopy acquired sports beverage maker BioSteel Sports Nutrition.
PURA management has recently reported Canadian inquiries
regarding various contractual opportunities with PURA’s leading
sports nutrition beverage EVERx CBD Sport Water. While other
companies are looking to get into the $50 billion sports nutrition
sector, PURA has over two years of experience producing and selling
its EVERx product.
Multiple surveys indicate consumers are
eager to purchase edibles and beverages. Specifically, a
study conducted by research firm Deloitte reported that over half of
surveyed respondents were likely to try cannabis-edibles, and 37%
were likely to try cannabis-beverages. PURA commissioned its own survey on the cannabis
beverage sector that is available for review
online.
In addition to the inquiries from Canada
about PURA’s EVERx reported by management, PURA has a ready partner
of its own as an entry into the Canada 2.0 market opportunity.
The CEO of PURA, Brian Shibley, is also the CEO of PURA
spinoff, Nouveau (NOUV)
a cannabis cultivator with a licensed operation in Canada.
NOUV’s Canadian operation is small today, but still gives PURA
access to Canada 2.0 while evaluating other suitors that may give
PURA accelerated access to the Canada 2.0
market.
PURA has reported over $1 million in CBD
beverage sales in the first six months of 2019 after reporting
approximately $1 million in sales for all of 2018. On top of
its ongoing sales, PURA has signed a new European
distribution agreement anticipated to generate $4 million
annually with a first shipment scheduled later this
month. PURA has also recently announced a new distribution agreement in Latin
America.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
Real-Time news about Nouveau Life Pharmaceuticals Inc (PK) (OTCMarkets): 0 recent articles
Plus d'articles sur Nouveau Life Pharmaceuticals, Inc. (PN)